ReviewWorld journal of clinical cases2015
Giant cell arteritis: Current treatment and management.
Review in World journal of clinical cases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02523625 (Can we Use Ultrasound in the Diagnosis and Monitoring of Patients With Giant Cell Arteritis?), which is not on this map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Can we Use Ultrasound in the Diagnosis and Monitoring of Patients With Giant Cell Arteritis?
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Bilateral juvenile temporal arteritis: a case-based review.Rheumatology international · 2024Pooled it
- European Headache Federation recommendations for neurologists managing giant cell arteritis.The journal of headache and pain · 2020Pooled it
- Diagnostic delay for giant cell arteritis - a systematic review and meta-analysis.BMC medicine · 2017Pooled it
- Thromboembolic events in giant cell arteritis: a scoping review.Annals of medicine and surgery (2012) · 2026Review
- Ocular Manifestations and Visual Outcomes of Patients with Giant Cell Arteritis.Journal of ophthalmology and advance research · 2026Article
- Posterior ischemic optic neuropathy as the main manifestation of giant cell arteritis: a case-based literature review.Reumatologia · 2026Article
- Measurement of the impact of giant cell arteritis and treatment with glucocorticoids on health-related quality of life.Therapeutic advances in musculoskeletal disease · 2026Review
- Ocular Manifestations of Giant Cell Arteritis.Advances in ophthalmology and optometry · 2025Article
- Utilising multiple discharge coding will improve identification of patients with giant cell arteritis: a retrospective analysis of a hospital discharge dataset.Rheumatology international · 2025Article
- Neuro-ophthalmic Manifestations of Giant Cell Arteritis: A Review.Journal of ophthalmic & vision research · 2025Review
- Risk Factors and Pharmacological Interventions Impacting Cerebrovascular Ischemic Events in Giant Cell Arteritis: A Narrative Review.Immunity, inflammation and disease · 2025Review
- Diagnostic Dilemmas in Giant Cell Arteritis: Overcoming Anchoring Bias.Case reports in rheumatology · 2025Article
- Review
- Investigating interferon type I responses in patients with suspected giant cell arteritis and polymyalgia rheumatica.Clinical and experimental immunology · 2024Article
- Article
- Recurrent Vision Loss in a Patient with Giant Cell Arteritis while on High Dose Corticosteroids.Journal of Brown hospital medicine · 2024Article
- Atypical giant cell arteritis presentations diagnosed with FDG-18 whole body PET imaging.BMJ case reports · 2023Article
- From Temporal Cell Arteritis to Giant Cell Aortitis Presenting as a Constitutional Syndrome: A Case Report.Cureus · 2023Article
- Article
- Temporal Artery Biopsy Debate: Positive TAB Result Prolongs Steroid Use in Giant Cell Arteritis.Plastic and reconstructive surgery. Global open · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoids remain the cornerstone of medical therapy in giant cell arteritis (GCA) and should be started immediately to prevent severe consequences of the disease, such as blindness. However, glucocorticoid therapy leads to significant toxicity in over 80% of the patients. Various steroid-sparing agents have been tried, but robust scientific evidence of their efficacy and safety is still lacking. Tocilizumab, a monoclonal IL-6 receptor blocker, has shown promising results in a number of case series and is now being tested in a multi-centre randomized controlled trial. Other targeted treatments, such as the use of abatacept, are also now under investigation in GCA. The need for surgical treatment is rare and should ideally be performed in a quiescent phase of the disease. Not all patients follow the same course, but there are no valid biomarkers to assess therapy response. Monitoring of disease progress still relies on assessing clinical features and measuring inflammatory markers (C-reactive protein and erythrocyte sedimentation rate). Imaging techniques (e.g., ultrasound) are clearly important screening tools for aortic aneurysms and assessing patients with large-vessel involvement, but may also have an important role as biomarkers of disease activity over time or in response to therapy. Although GCA is the most common form of primary vasculitis, the optimal strategies for treatment and monitoring remain uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.